InfuSystem (NYSE:INFU) Now Covered by B. Riley

B. Riley began coverage on shares of InfuSystem (NYSE:INFU) in a research report released on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $13.00 price target on the stock.

Separately, StockNews.com upgraded InfuSystem from a buy rating to a strong-buy rating in a research note on Friday, September 20th.

InfuSystem Stock Up 2.9 %

INFU stock opened at $6.75 on Thursday. InfuSystem has a twelve month low of $5.74 and a twelve month high of $10.99. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.07 and a quick ratio of 1.64. The company has a market cap of $143.74 million, a P/E ratio of -675,000.00 and a beta of 1.46.

InfuSystem (NYSE:INFU) last posted its earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $33.70 million during the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.

Hedge Funds Weigh In On InfuSystem

Institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers lifted its position in InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after purchasing an additional 2,145 shares in the last quarter. Marshall Wace LLP purchased a new position in InfuSystem during the second quarter valued at $131,000. Oppenheimer Asset Management Inc. lifted its position in InfuSystem by 52.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company’s stock valued at $178,000 after purchasing an additional 8,917 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in InfuSystem during the second quarter valued at $208,000. Finally, ARS Investment Partners LLC lifted its position in InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after purchasing an additional 3,422 shares in the last quarter. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.